Allogene Therapeutics advances its proprietary allogeneic CAR T platform targeting oncology and autoimmune diseases, with pivotal readouts expected in Q2 2026. The ALPHA3 Phase 2 trial for cema-cel in first-line large B-cell lymphoma represents a potential inflection point, while other pipeline candidates explore autoimmune and solid tumor indications. The company remains in a developmental stage with ongoing net losses but improving financial metrics, supported by its in-house Cell Forge 1 manufacturing facility. Investors should monitor clinical safety signals, regulatory developments, and capital allocation as the company approaches key milestones.